Chit Chat Stocks cover image

DexCom (Ticker: DXCM) with Nick Sciple

Chit Chat Stocks

00:00

Dexcom Diabetes - How Can Multiple Contraction Kill Returns?

CGM fails to become standard of care in diabetes and new markets. Multiple contraction could kill returns. If the market decides to bring the sales multiple or the valuation multiple in close to that 10x sales range, that's going to be a big headwind to performance. And then lastly, if Dexcom hits a wall when it comes to kind of product improvements and price reduction.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app